Day 2 - Friday 5th May 2023

9th Market Access, Pricing & Reimbursement Global Congress 2023 Europe

Trends and Strategies to Achieve Optimum Patient Access to Healthcare


  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship

Claudia Neuber, Head, Global Pricing Oncology, Global Market Access & Pricing, AstraZeneca

  • Why is this important?
  • Current state of play
  • Barriers to Equity Pricing
  • Potential solutions and some principles to maximize impact of Equity Pricing
  • Innovative approaches required to address the medicine access challenge
  • Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
  • The value of list prices against the backdrop of external price referencing and managed entry agreements.
  • Innovative policy options that needs to be developed, agreed upon and implemented.
  • Keeping on top of pricing and market access trends
  • Identify a clinical or economic advantage and generate the appropriate clinical and health economic evidence to support a strong value proposition
  • Optimising the use of Patient-Reported Outcomes
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Challenges in drug pricing and reimbursement
  • How to navigate a complex balance between financial and strategic risks
  • Strategies to offset regulatory and inflationary pressures.
  • Addressing environmental, social, and corporate governance issues
  • Encouraging cross-functional or cross-company collaborations
  • The increasing relevance of Emerging Markets
  • EMs Embrace Technological Innovation
  • Creating value through partnership
  • How to Avoid the Pitfalls of Innovation in Emerging Markets
  • Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to innovative therapies
  • Why is the full stakeholder ecosystem important for gaining access in the future?
  • How to Identify the stakeholder ecosystem for access success
  • Step by step: Setting up a cross-functional program for access success
  • Assessment of financial benefit from tendering
  • Evaluating its impact on prices and market concentration
  • Consideration of its operational framework
  • Tendering for pharmaceuticals as a reimbursement tool
  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • International Drug Price Indicator Guide WHO
  • Increasing collaboration between EU countries
  • Frontiers in Health Care
  • What will the future bring?
Scroll to Top
Scroll to Top